1. Home
  2. TALO vs STOK Comparison

TALO vs STOK Comparison

Compare TALO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

HOLD

Current Price

$11.02

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$32.17

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
STOK
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TALO
STOK
Price
$11.02
$32.17
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$14.30
$33.11
AVG Volume (30 Days)
2.2M
1.0M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.68
Revenue
$1,872,554,000.00
$205,632,000.00
Revenue This Year
N/A
$430.24
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$46.53
Revenue Growth
0.06
1128.17
52 Week Low
$6.23
$5.35
52 Week High
$12.20
$38.69

Technical Indicators

Market Signals
Indicator
TALO
STOK
Relative Strength Index (RSI) 49.23 53.64
Support Level $10.64 $31.50
Resistance Level $11.39 $33.90
Average True Range (ATR) 0.37 2.25
MACD -0.11 -0.15
Stochastic Oscillator 24.44 38.02

Price Performance

Historical Comparison
TALO
STOK

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: